Download Files:
MDA 19
SKU
HY-15451-10 mg
Category Reference compound
Tags Cannabinoid Receptor, GPCR/G Protein;Neuronal Signaling, Neurological Disease
$66 – $384
Products Details
Product Description
– MDA 19 is a potent and selective agonist of human cannabinoid receptor 2 (CB2), with a Ki of 43.3 nM. MDA 19 has antiallodynic effects in a rat model of neuropathic pain and does not affect rat locomotor activity[1][2].
Web ID
– HY-15451
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C21H23N3O2
References
– [1]Diaz, Philippe; Xu, Jijun; Astruc-Diaz, Fanny et al. Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain. Journal of Medicinal Chemistry (2008), 51(16), 4932-4947.|[2]Xu JJ, Diaz P, Astruc-Diaz F et al. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg. 2010 Jul;111(1):99-109.
CAS Number
– 1048973-47-2
Molecular Weight
– 349.43
Compound Purity
– 98.22
SMILES
– O=C(N/N=C1C(N(CCCCCC)C2=C1C=CC=C2)=O)C3=CC=CC=C3
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 14.29 mg/mL (ultrasonic)
Target
– Cannabinoid Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.